報價延遲最少15分鐘:2024/06/21 01:03 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
20.96 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.66/-3.17
|
|
企業價值
1.15B
|
| 資產負債 |
|
每股賬面淨值
2.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
76.99M
|
|
每股收益
1.12
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/21 01:03 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. |